Skip to main content
. 2021 Sep 3;160(3):e289–e293. doi: 10.1016/j.chest.2021.04.055

Figure 2.

Figure 2

Initial 18F-FDG PET-CT demonstrating significant avidity within the left axillary lymphadenopathy (A) and right hilar mass (B). Repeat study 4 weeks after initial image demonstrating significant reduction in avidity of left axillary lymphadenopathy(C) with stable findings in right hilar mass (D). 18F-FDG = fludeoxyglucose F 18 Injection.